All
FDA to Expedite Review of Novel Drug in Subset of Metastatic Breast Cancer
July 21st 2022Investigators are analyzing the novel drug, OP-1250, both as a single-agent treatment option and in combination with Ibrance in patients with recurrent, locally advanced or metastatic ER-positive/HER2-negative breast cancer.
Keytruda Treatment Regimen Misses Survival Goal in Head and Neck Cancer
July 20th 2022The addition of Keytruda to chemoradiation, followed by maintenance Keytruda, did not lead to a statistically significant event-free survival benefit in patients with locally advanced head and neck squamous cell carcinoma.
Sarcoma Deserves More Attention in the Spotlight
July 20th 2022Even in the public health shadows of the more common cancers like breast cancer, for the few but strong patients with a sarcoma diagnosis, we are obligated to spread awareness, restore hope and with specialist care, ensure the best possible outcomes.
Recovering From Esophageal Cancer Surgery is ‘Grueling’ But Doable, Says Survivor
July 19th 2022An esophageal cancer survivor noted that recovering from surgery to treat the disease was “grueling,” but he said he was eventually able to return to some normalcy with his ability to eat his favorite foods.
Cosela May Decrease Chemo-Related Blood Complications During Lung Cancer Treatment
July 18th 2022Cosela tended to decrease myelosuppressive events — when the bone marrow is not working sufficiently to produce blood cells and platelets — in patients receiving chemotherapy for extensive-stage small cell lung cancer.
FDA Fast Tracks Investigational Drug for the Treatment of Recurrent Brain Cancer
July 15th 2022The safety, optimal dosage and efficacy of the investigational drug is currently being evaluated in a first-in-human trial in patients with recurrent high-grade glioblastoma, a type of spinal cord and brain cancer.
FDA Lifts Hold on Trial Investigating Novel Drug in Patients With High-Risk Breast Cancer
July 14th 2022The FDA has permitted the manufacturer of a novel drug to continue a phase 3 clinical trial investigating the effects of treatment with a novel drug in patients with HER2/neu-positive primary breast cancer.